NAMS vs IRTC Comparison

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.